Why it matters: For years the honest answer on vaping and cancer was that it was too soon to know, because the cancers that smoking causes take decades to appear and vaping is too recent for that evidence to have accumulated. This review does not claim that gap has been filled. Instead it argues that the indirect evidence, the DNA damage, the animal tumors, and the mechanisms, has reached the point where the most reasonable scientific judgment is that these products are probably carcinogenic. The single most important word in the finding is "likely," and the Lumen Standard requires carrying it rather than flattening it to "causes."
What the review found and what "likely" means
The paper, titled "The carcinogenicity of e-cigarettes: a qualitative risk assessment," is a structured weighing of the evidence rather than a new experiment, drawing on more than 100 studies. Its conclusion, in the authors' words, is that "nicotine-based e-cigarettes are likely to be carcinogenic to humans who use them." In evidence terms, "likely" sits below "established" or "proven." It signals that the body of indirect evidence points consistently in one direction, while the direct proof, human cancer cases counted over time, is not yet available.

What kinds of evidence were weighed, and the limits of eachThe review, restricted to publications since 2017 to limit selection bias, drew on three kinds of evidence. Human studies were mainly biomarkers of exposure and of harm: the authors describe DNA damage correlated with vape-derived metabolites of carcinogens including nicotine-derived nitrosamines, volatile organic compounds, flavour-derived agents, and certain metals, along with markers of oxidative stress, epigenetic change, and inflammation in oral and respiratory tissue. Animal evidence included rodent inhalation studies described as producing lung adenocarcinomas in mice. Mechanistic evidence was organized using the key characteristics of carcinogens, the framework the World Health Organization's International Agency for Research on Cancer uses to reason about causation. Each of these has a ceiling: biomarkers show biological harm but not a diagnosed tumor, animal cancers do not automatically transfer to humans, and mechanisms explain plausibility rather than count cases.

What we still do not knowThe gap that this review cannot close is long-term human cancer incidence. No body of evidence yet tracks large numbers of people who vape, but do not smoke, for the years it takes a cancer to develop and be diagnosed. Until that exists, the strongest defensible statement is the one the authors make: likely, not proven.
The tobacco parallel, and why timing matters for policyThe authors note that across reviews from 2017 to 2025, the scientific conclusion shifted from a call for more evidence toward active concern about e-cigarette carcinogenicity. The implicit parallel is to tobacco, where a delay of decades between use and proof of harm carried an enormous cost. The policy argument is about timing: whether to act on a "likely" judgment now rather than wait for the human cancer counts that, by definition, can only arrive later. Two of the same authors develop this parallel directly in a companion paper, Sitas and Stewart, "Historical parallels between harms of tobacco and e-cigarettes," in Cancer Epidemiology. 
What this means for people who vapeFor current users, the practical reading is cautious, not alarmist. The evidence now leans toward real cancer risk, the magnitude is unquantified, and the comparison with smoking is not settled by this review. For scale, the World Health Organization's first global estimate of e-cigarette use, released in October 2025, counts more than 100 million vapers worldwide, about 86 million of them adults, with global adult vaping prevalence near 1.9%.